Assessment included chest computed tomography imaging to evaluate structural changes in the lungs due to treatment.
Findings highlight the potential for achieving clinical remission in severe asthma patients with tezepelumab, though larger trials are warranted.
Abstract
In summary, tezepelumab induced significant benefits in patients with severe asthma in this real-world cohort, improving symptoms, lung function, and radiological outcomes.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Tezepelumab in severe asthma: chest computed tomography assessment of airway remodeling and clinical remission | Synapse